Canakinumab
Top View
- Inflammatory Conditions – Ilaris® (Canakinumab for Subcutaneous Injection)
- Drug Class Review Targeted Immune Modulators
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Ilaris, INN-Canakinumab
- (INN) for Biological and Biotechnological Substances
- Long-Term Safety and Effectiveness of Canakinumab Therapy
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- Struggles with Clinical Translation of Immune Intervention Trials Diabetes Care 2014;37:1173–1175 | DOI: 10.2337/Dc13-2878 Jay S
- Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderate-To-Severe Plaque Psoriasis
- The Way Forward for the Refractory Asthmatic
- Effect of Disease Modifying Anti-Rheumatic Drugs On
- Anti-IL-1Β (Canakinumab), Human Igg1 Antibody
- Utah Medicaid Pharmacy and Therapeutics Committee Drug
- ILARIS® (Canakinumab)
- Prediction of Clearance of Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins in Children: Application of Allometric Scaling
- Ilaris ® (Canakinumab) Medical Policy (PDF)
- PATIENT FACT SHEET (Ilaris)